These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2955602)

  • 21. [Vital capillary microscopic examination and transcutaneous pO2-measurements by intravenous prostaglandin E1 infusion].
    Heidrich H; Lammersen T
    Dtsch Med Wochenschr; 1985 Aug; 110(34):1283-5. PubMed ID: 4040847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
    Weiss T; Griesshaber J; Rogatti W; Kistner O; Hsu E; Jansen T; Diehm C
    Vasa Suppl; 1991; 33():341-2. PubMed ID: 1788749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hemodynamic effects of intermittent intra-arterial infusion treatment with prostaglandin E1 in peripheral arterial occlusive disease].
    Ranke C; Creutzig A; Alexander K
    Med Klin (Munich); 1991 Jul; 86(7):349-52, 382. PubMed ID: 1921896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous prostavasin--therapy in peripheral arterial occlusive disease in Fontaine's stages III and IV. Early and late results of a screening study.
    Heidrich H; Meuche C; Ranft J; Rummel S; Peters A
    Prog Clin Biol Res; 1989; 301():411-6. PubMed ID: 2678131
    [No Abstract]   [Full Text] [Related]  

  • 25. [Prostaglandin E1 in therapy of peripheral arterial occlusive disease].
    Sinzinger H; Rogatti W
    Wien Klin Wochenschr; 1991; 103(18):558-65. PubMed ID: 1750223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
    Heidrich H
    Vasa Suppl; 1991; 33():346-7. PubMed ID: 1788752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Reflex oximetry for evaluating blood redistribution in patients with arterial occlusive disease treated with PGE1].
    Thum J; Caspary L; Creutzig A; Alexander K
    Vasa Suppl; 1992; 35():39-41. PubMed ID: 1481056
    [No Abstract]   [Full Text] [Related]  

  • 28. On the metabolism of prostaglandin E1 administered intravenously to human volunteers.
    Peskar BA; Cawello W; Rogatti W; Rudofsky G
    J Physiol Pharmacol; 1991 Sep; 42(3):327-31. PubMed ID: 1793892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Controlled long-term blood pressure measurement with intravenous prostaglandin E1 infusion].
    Heidrich H; Brodel C; Meuche C; Hellmann M; Ranft J
    Vasa; 1991; 20(1):13-6. PubMed ID: 2031393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of prostaglandin E1 on function and deformability of neutrophilic granulocytes in patients with stage IV peripheral arterial occlusive disease].
    Neumann FJ; Diehm C; Müller-Bühl U; Weiss T; Zimmermann R; Tillmanns H; Kübler W
    Vasa Suppl; 1989; 27():40-1. PubMed ID: 2623539
    [No Abstract]   [Full Text] [Related]  

  • 31. A new surgical approach to vasodilating therapy in peripheral occlusive vascular disease.
    Horch R; Krönung G
    Nihon Geka Hokan; 1988 Nov; 57(6):487-92. PubMed ID: 3268061
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of ischemic ulcers of the lower limbs with alprostadil (prostaglandin E1).
    Tondi P; Gerardino L; Santoliquido A; Pola R; Gabrielli M; Papaleo P; Gasbarrini A; Pola P; Flore R
    Dermatol Surg; 2004 Aug; 30(8):1113-7. PubMed ID: 15274701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pilot study of the effect of intravenous prostavasin therapy of inpatients with diabetes mellitus and IIb arterial occlusive disease].
    Rosak C; Hofmann U; König P; Nitsche GB
    Vasa Suppl; 1991; 33():339-40. PubMed ID: 1788748
    [No Abstract]   [Full Text] [Related]  

  • 34. Skin surface oxygen pressure fields during administration of prostaglandin E1 in patients with arterial occlusive disease.
    Creutzig A; Caspary L; Alexander K
    Klin Wochenschr; 1990 Feb; 68(4):207-12. PubMed ID: 2314008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Duplex ultrasound measurement of morphologic parameters before and following repeated puncture of the femoral artery for intermittent infusion therapy].
    Ranke C; Creutzig A; Alexander K
    Vasa; 1990; 19(3):203-6. PubMed ID: 2238813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacologic concepts for clinical use of prostaglandin E1].
    Schrör K
    Vasa Suppl; 1991; 33():335-6. PubMed ID: 1788746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
    Fitscha P; Simmet T; Peskar BA; Reuter H; Sinzinger H; Rogatti W; Tilsner V
    Wien Klin Wochenschr; 1988 Jul; 100(14):477-81. PubMed ID: 3062905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
    Balzer K; Rogatti W; Rüttgerodt K
    Vasa Suppl; 1989; 28():31-8. PubMed ID: 2609242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Placebo controlled study of the effect of intravenous PGE1 on macro- and microcirculation in patients with stage III/IV arterial occlusive disease].
    Scheffler P; de la Hamette D; Leipnitz G
    Vasa Suppl; 1991; 33():343-4. PubMed ID: 1788750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Duplex ultrasound measurement of hemodynamic parameters at rest and following arterial stenosis: effect of intra-arterial infusion therapy with prostaglandin E1].
    Ranke C; Creutzig A; Alexander K
    Vasa Suppl; 1989; 27():353-5. PubMed ID: 2696104
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.